The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.
AFP‑L3 can be detected in the serum of approximately 35 % of the patients with small HCC (< 2 cm).
AFP‑L3 is associated with a more aggressive tumor, shorter doubling time, infiltrative growth pattern, vascular invasion, and intrahepatic metastasis. A metanalysis showed that the overall sensitivity and specificity of AFP‑L3 in the diagnosis of HCC were 48.3 % (45.9‑50.7 %) and 92.9 % (91.6‑94.0 %), respectively. For the diagnosis of early-stage HCC, a meta‑analysis showed that the pooled sensitivity and specificity of AFP‑L3 were 34 % (30‑39 %) and 92 % (91‑93 %), respectively.
AFP‑L3 can be combined with other biomarkers such as prothrombin induced by vitamin K absence‑II (PIVKA‑II) and AFP to improve the diagnostic performance for HCC detection.
System Specifications:
▸ Testing Time: 27 minutes
▸ Sample volume: 38 µl
▸ Calibration: by 2‑point
▸ Measurement range: 0.605-1210 ng
